2022-07-29T20:13:48-05:00 2021-09-30 ERNST & YOUNG US LLP 200 CLARENDON STREET BOSTON MA 021165072 990 2020-10-01 042263040 Dana-Farber Cancer Institute Inc % MELISSA CHAMMAS DANA 6176323000 450 Brookline Avenue BP418 Boston MA 02215 MICHAEL L RENEY CFO & ASST TREASURER 6176326000 2022-07-26 true MICHAEL L RENEY 999009999 EMILY CINCOTTA P01272146 6172662000 2022-07-24 2 2020 2022-09-23 18:48:47Z Laurie H Glimcher MD 450 BROOKLINE AVE Boston MA 02215 2419108987 false X www.dana-farber.org X 1951 MA SEE SCHEDULE O 61 60 6996 600 93395 21930 629412126 726297460 1310450921 1571455891 1119608 260510 64222756 119781469 2005205411 2417795330 3795934 5380564 0 0 660439151 714320194 2561617 3975124 40626637 1302561710 1502166122 1969358412 2225842004 35846999 191953326 3905849954 4549977055 1750598738 1605907385 2155251216 2944069670 X SEE SCHEDULE O false false 1321859553 0 1571455891 Clinical Care - SEE SCHEDULE O 635971019 0 0 Research - SEE SCHEDULE O 31728016 5380564 0 Community Benefits - SEE SCHEDULE O 0 0 0 1989558588 true true false true false false false false false true true false false true true false false true false false true false false true true false true true true true true true false false false false false true false false false false true false false false true true true true true false true 634 0 true 6996 true true true true CJ false false false true true false false false false true false X 61 60 true false false false false false false true true false false true true true true true true true true false AL AK AZ CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X MELISSA CHAMMAS 6176326000 450 BROOKLINE AVE BP418 Boston MA 02115 X Glimcher Laurie H MD Trustee, President and CEO 44.0 6.0 X X 1724225 0 302393 Benz Edward J JR MD President and CEO Emeritus 50.0 0.0 X 1133382 0 57427 Reney Michael L CFO and Asst. Treasurer 46.0 4.0 X 829041 0 43894 Hahn William MD PHD COO & EVP 50.0 0.0 X 799032 0 43460 Terwilliger James FORMER COO & EVP 48.0 2.0 X 815197 0 24858 Bunnell Craig A MD CHIEF MEDICAL OFFICER 50.0 0.0 X 776215 0 46443 Winer Eric MD Chief of Div of WMNS CANCERS 50.0 0.0 X 760184 0 54768 Soiffer Robert MD Chief of Hemotologic Malig. 50.0 0.0 X 722519 0 59949 DUVAL MELANY SVP OF DEVELOPMENT 50.0 0.0 X 697803 0 73719 Constantine Michael MD Milford Med Dir-Hematol Onc 50.0 0.0 X 700983 0 61137 Johnson Bruce MD CHIEF CL RES OFF(END 9/1/21) 50.0 0.0 X 679531 0 61539 Boskey Richard S ESQ ASST. SEC. & GC (END 12/14/20) 45.0 5.0 X 652019 0 68313 Griffin James D MD PROFESSOR OF MEDICINE 50.0 0.0 X 642164 0 65398 Rollins Barrett J MD PHD SNR ADVISOR TO PRESIDENT & CEO 50.0 0.0 X 590875 0 60481 Megdal Maria SVP of Institute Operations 50.0 0.0 X 527540 0 58592 Stone Richard M MD PROFESSOR OF MEDICINE 50.0 0.0 X 494776 0 68441 Liebow Elizabeth CHIEF STRATEGY OFFICER 50.0 0.0 X 464291 0 66047 Memmott Drew SVP RESEARCH ADMINISTRATION 50.0 0.0 X 464783 0 63038 Meyerhardt Jeffrey CHIEF CL RES OFF(as of 9/1/21) 50.0 0.0 X 428226 0 73601 Haigis Kevin Chief Scientific Officer 50.0 0.0 X 459668 0 3588 Gettleman Wendy VP of Facilities MGMT & RE 50.0 0.0 X 348087 0 65137 Bartel Sylvia RPH MHP VP of Pharmacy Services 50.0 0.0 X 327046 0 64942 Ebert Benjamin MD PHD Chair of Medical Oncology 50.0 0.0 X 200400 0 8311 Ryan John Asst Sec. & GC(as of 12/14/20) 45.0 5.0 X 80838 0 2016 ALEXANDER SUSAN ESQ Trustee 1.0 0.0 X 0 0 0 Bekenstein Joshua Trustee & Chairman 2.0 0.0 X X 0 0 0 BERGER HARVEY MD Trustee 1.0 0.0 X 0 0 0 Berkowitz Roger Trustee 1.0 0.0 X 0 0 0 Berylson Amy Trustee 1.0 0.0 X 0 0 0 Beschloss Afsaneh Trustee 1.0 0.0 X 0 0 0 Blum Betty Ann Trustee 1.0 0.0 X 0 0 0 Brock-Wilson Jane Trustee 1.0 0.0 X 0 0 0 Chandra Monica Trustee & Secretary 2.0 0.0 X X 0 0 0 Cohen Timothy Trustee 1.0 0.0 X 0 0 0 DALEY KAREN PHD MPH RN FANN Trustee 1.0 0.0 X 0 0 0 DaSilva Kevin Trustee 1.0 0.0 X 0 0 0 Eisenson Michael Trustee (As of 2/3/21) 1.0 0.0 X 0 0 0 Fine Stephen Trustee 1.0 0.0 X 0 0 0 Forbes Moira Trustee (As of 2/3/21) 1.0 0.0 X 0 0 0 Gibson Nancy Trustee 1.0 0.0 X 0 0 0 Greenthal Jill Trustee 1.0 0.0 X 0 0 0 Gross Phillip Trustee 1.0 0.0 X 0 0 0 Hadley Christopher Trustee 1.0 0.0 X 0 0 0 Jaffe Alison Trustee 1.0 0.0 X 0 0 0 Jamieson Jane Trustee 1.0 0.0 X 0 0 0 Janower Andrew Trustee 1.0 0.0 X 0 0 0 KAPLAN ANDREW Trustee 1.0 0.0 X 0 0 0 Knez Brian Trustee 1.0 0.0 X 0 0 0 Koppel Steven Trustee 1.0 0.0 X 0 0 0 KOSTER STEPHEN ESQ Trustee 1.0 0.0 X 0 0 0 KYLE AMY ESQ Trustee 1.0 0.0 X 0 0 0 Lotane Nancy Trustee 1.0 0.0 X 0 0 0 Lubin Richard Trustee & Vice-Chairman 2.0 0.0 X X 0 0 0 Lucas Bradley Trustee 1.0 0.0 X 0 0 0 Lucchino Lawrence Trustee (Term ended 2/3/21) 1.0 0.0 X 0 0 0 Marcus Paul Trustee 1.0 0.0 X 0 0 0 Martin Demond Trustee 1.0 0.0 X 0 0 0 MCCAIN TRACEY ESQ Trustee 1.0 0.0 X 0 0 0 McCann James Trustee (As of 2/3/21) 1.0 0.0 X 0 0 0 MEDEL ROGER MD Trustee 1.0 0.0 X 0 0 0 MILLER ERIC PHD Trustee 1.0 0.0 X 0 0 0 Norberg Joseph Trustee 1.0 0.0 X 0 0 0 O'Connor John TRUSTEE & Treasurer 2.0 0.0 X X 0 0 0 Packman Karen Linde Trustee 1.0 0.0 X 0 0 0 Palandjian Peter Trustee 1.0 0.0 X 0 0 0 Pasquarello Theodore Trustee 1.0 0.0 X 0 0 0 Penrose Fatima Trustee 1.0 0.0 X 0 0 0 Perini Jennifer Trustee 1.0 0.0 X 0 0 0 PERLMUTTER STEVEN ESQ Trustee (Term Ended 5/24/21) 1.0 0.0 X 0 0 0 Poduska Susan Trustee 1.0 0.0 X 0 0 0 Reynolds Robert Trustee 1.0 0.0 X 0 0 0 SACHS ROBERT ESQ Trustee 1.0 0.0 X 0 0 0 Schlager Eric Trustee 1.0 0.0 X 0 0 0 Sen Laura Trustee 1.0 0.0 X 0 0 0 Stansky Robert Trustee 1.0 0.0 X 0 0 0 STRATFORD SANDRA MD MSC TRUSTEE 1.0 0.0 X 0 0 0 Stecher Esta Trustee 1.0 0.0 X 0 0 0 Sullivan Ronald Trustee 1.0 0.0 X 0 0 0 Svanberg Louise Trustee 1.0 0.0 X 0 0 0 Terrana Beth Trustee 1.0 0.0 X 0 0 0 Tocio Mary Ann Trustee 1.0 0.0 X 0 0 0 Trotsky Michael Trustee 1.0 0.0 X 0 0 0 TULI SUSHIL Trustee 1.0 0.0 X 0 0 0 Walker Jodi Trustee 1.0 0.0 X 0 0 0 Whelan Lori Trustee 1.0 0.0 X 0 0 0 Williams Frederica Trustee 1.0 0.0 X 0 0 0 15318825 0 1497492 1673 true true false Mass General Brigham INC 399 Revolution Drive Ste 645 SOMERVILLE MA 02145 INFORMATION SYS 91011252 BRIGHAM AND WOMEN'S HOSPITAL 399 Revolution Drive Ste 645 SOMERVILLE MA 02145 MEDICAL SERVICES 76953920 WALSH BROTHERS INC 200 Commercial Street BOSTON MA 02190 BUILDING CONTRACTOR 50485417 Cardinal Health 736 Cambridge Street BRIGHTON MA 02135 MEDICAL SERVICES 39036057 BRIGHAM AND WOMEN'S PHYSICIANS ORG 75 Francis Street BOSTON MA 02115 MEDICAL SERVICES 15144180 524 200807 15599692 207559702 502937259 20527341 726297460 NET PATIENT SERVICE REVENUE 621110 1564202278 1564202278 NETWORK COLLABORATION 900099 6388781 6388781 LINAC 621500 864832 864832 1571455891 120197 120197 0 111088013 111088013 2207493 2207493 0 2207493 2207493 140313 140313 140313 140313 256368 15599692 1313657 -1057289 -1057289 0 0 0 0 0 0 PARKING LOT REVENUE 812930 3167144 3167144 FOOD SERVICE REVENUE 722210 2516332 2516332 WCB BOUTIQUE REVENUE 446199 698598 698598 1161178 93395 1067783 7543252 2417795330 1571455891 93395 119948584 3339220 3339220 2041344 2041344 0 0 9120546 3461961 4960782 697803 4014593 1601231 2413362 573990840 482976987 65563006 25450847 24960752 19038502 4800037 1122213 62291802 47512293 11978925 2800584 39941661 30465004 7680915 1795742 6746026 5806405 939621 19615445 13880237 5650892 84316 758556 758556 531835 531835 3975124 3975124 0 207634923 184317997 21854274 1462652 15468791 12881187 1110550 1477054 30468988 25407673 4040102 1021213 64876721 62877007 1951633 48081 0 134755738 108771421 25981449 2868 6032793 5825222 185168 22403 0 2926095 705462 1676217 544416 21410142 21105656 304486 0 97911944 88003883 9908061 5349207 24051 5325156 PHARMACEUTICALS 724785630 724785630 MISCELLANEOUS 40633407 22640542 17871544 121321 MEDICAL SUPPLIES 91215945 90513902 702043 OTHER PATIENT CARE EXPENSE 31043936 31043936 2225842004 1989558588 195656779 40626637 0 0 132413899 152104020 116972121 76057876 163645048 213493799 1147770 860126 0 0 0 0 57707055 66954755 54445075 64357187 2101809014 1098133350 1046046153 1003675664 0 0 0 0 0 0 7894580 7894580 2325578253 2964579048 3905849954 4549977055 328417243 305173992 0 0 0 0 509041424 501804498 0 0 0 0 74622792 72978317 0 0 838517279 725950578 1750598738 1605907385 X 1020655661 1354436047 1134595555 1589633623 2155251216 2944069670 3905849954 4549977055 X 191953326 596865128 X false true X true true true X 511844582 561378936 604363420 629412126 726297460 3033296524 0 0 511844582 561378936 604363420 629412126 726297460 3033296524 0 3033296524 9251603 9629978 101304972 52614894 113415703 286217150 88157 126581 93395 308133 17212855 23432437 14052058 14915439 7706225 77319014 3397140821 6332816228 0.89290 0.91046 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true true false true false true 310411 true 221424 false false 531835 false SCHEDULE C, PART II-B VAN SCOYOC & ASSOCIATES PROVIDED FEDERAL LEGISLATIVE CONSULTING FOR DANA-FARBER CANCER INSTITUTE, INC. (DFCI). MCDERMOTT, QUILTY & MILLER, LLP PROVIDED STATE LEGISLATIVE AND GOVERNMENT RELATIONS CONSULTING ON HEALTH INTERESTS TO DFCI. CONFERENCE OF BOSTON HOSPITALS PROVIDED STATE AND FEDERAL LOBBYING SUPPORT TO DFCI. ALLIANCE OF DEDICATED CANCER CENTERS REPRESENTS THE NATION'S TEN FREESTANDING CANCER CENTERS. WE WORK TOGETHER ON FEDERAL REGULATORY, LEGISLATIVE, AND REIMBURSEMENT ISSUES UNIQUE TO DEDICATED CANCER CENTERS. CQ ROLL CALL PROVIDES GRASSROOTS ADVOCACY SOFTWARE USED FOR EMAILS AND ACTION ALERTS ON ADVOCACY ISSUES WHICH ARE SENT TO MEMBERS OF DANA-FARBER'S LEGISLATIVE ACTION NETWORK (LAN). DFCI'S LAN ADVOCATES FOR LEGISLATION AND POLICIES THAT IMPROVE THE LIVES OF CANCER PATIENTS. DFCI IS A MEMBER OF THE AMERICAN HOSPITAL ASSOCIATION AND THE MASSACHUSETTS HOSPITAL ASSOCIATION, NOT-FOR-PROFIT ORGANIZATIONS THAT REPRESENT AND ADVOCATE FOR THE COLLECTIVE INTERESTS OF THEIR MEMBER HOSPITALS AND HEALTH SYSTEMS THROUGH LEADERSHIP IN PUBLIC ADVOCACY, EDUCATION, AND INFORMATION. A PORTION OF THE MEMBERSHIP DUES TO THESE ORGANIZATIONS ARE USED FOR LOBBYING ACTIVITIES. ON OCCASION, DFCI EXECUTIVE LEADERSHIP MEET WITH STATE AND FEDERAL ELECTED OFFICIALS TO ADVOCATE FOR THE PASSAGE OF LEGISLATION AND FUNDING TO ADVANCE CANCER RESEARCH AND TREATMENT, AND LEGISLATION TO SUPPORT SERVICES FOR CANCER PATIENTS AND CANCER SURVIVORS. IN ADDITION, DFCI SUBMITS LETTERS AND/OR TESTIMONY TO ELECTED OFFICIALS AND POLICY MAKERS ON THESE ISSUES. 357421000 14528000 122237000 14990000 479196000 313020000 21879000 41043000 18521000 357421000 301578000 11140000 18454000 18152000 313020000 276248000 12288000 30131000 17089000 301578000 252162000 9815000 32600000 18329000 276248000 0.52710 0.47290 false true true 7640445 7640445 1274227950 613522748 660705202 322573680 120735998 201837682 455740009 363874604 91865405 41626930 41626930 1003675664 INTEREST IN DANA-FARBER, INC. 2427985539 RIGHT OF USE - NET OP. LEASES 373686996 RESEARCH RECEIVABLES 72312481 INTEREST IN DFCCN 45812000 MISCELLANEOUS ASSETS 44782032 2964579048 0 OPERATING LEASE LIABILITIES 394937070 RESEARCH ADVANCES 131125853 MISCELLANEOUS LIABILITIES 86757458 SWAP VALUATION LIABILITY 59630000 AMOUNTS DUE 3RD PARTY PAYOR 50808197 PROV FOR MED MALPRACTICE CLAIM 2692000 725950578 SCHEDULE D, PART V, LINE 4 USES OF ENDOWMENT FUNDS DANA-FARBER, INC. (DFI) A RELATED ORGANIZATION OF DANA-FARBER CANCER INSTITUTE, INC. (DFCI) HOLDS THE ENDOWMENTS FOR DFCI. AS DESCRIBED IN THE CONSOLIDATED AUDITED FINANCIAL STATEMENTS, DFCI'S ENDOWMENTS CONSIST SOLELY OF DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR PURPOSES DIRECTLY RELATED TO DFCI'S EXEMPT MISSION AND PURPOSES. AS REQUIRED BY GENERALLY ACCEPTED ACCOUNTING PRINCIPLES, NEW ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OF DONOR-IMPOSED RESTRICTIONS. ALL USES OF DFCI'S ENDOWMENT FUNDS ARE IN FURTHERANCE OF DFCI'S EXEMPT MISSION AND PURPOSES. South Asia 0 0 Program Services SUBCONTRACTED RESEARCH 395023 North America 0 0 Program Services SUBCONTRACTED RESEARCH 1333377 Sub-Saharan Africa 0 0 Program Services SUBCONTRACTED RESEARCH 177976 Europe (Including Iceland and Greenland) 0 0 Program Services SUBCONTRACTED RESEARCH 2472413 East Asia and the Pacific 0 0 Program Services SUBCONTRACTED RESEARCH 1272237 Middle East and North Africa 0 0 Program Services SUBCONTRACTED RESEARCH 86033 South America 0 0 Program Services SUBCONTRACTED RESEARCH 286271 East Asia and the Pacific 0 0 Program Services RESEARCH AND EDUCATION 1239192 South America 0 0 Program Services RESEARCH AND EDUCATION 447547 0 0 0 0 7710069 7710069 false false true false false true X X X X X X X true TRUESENSE MARKETING 155 COMMERCE DR FREEDOM PA 15042 Direct Mail false 16767616 3827309 12940307 Grenzebach Glier Assoc 200 SOUTH MICHIGAN AVE STE 2100 CHICAGO IL 60604 Consulting false 0 147815 0 16767616 3975124 12940307 All States WALK 7144828 7112243 32585 630 414 872602 RADIO-TELETHON 3973402 3973402 22649 716 159739 7 4737830 4514047 223783 1550 1971 253386 15856060 15599692 256368 24829 3101 1285727 1313657 -1057289 true true X true X true X true true true false true true 19162944 -11429284 7733660 0.00350 109666403 -74521231 35145172 0.01580 128829347 -85950515 42878832 0.01930 5347898 5347898 0.00240 5928888 -847436 5081452 0.00230 698643902 -563952257 134691645 0.06050 3059984 3059984 0.00140 712980672 -564799693 148180979 0.06660 841810019 -650750208 191059811 0.08590 2307767 2307767 0.00120 524900 524900 0.00030 2832667 2832667 0.00150 true 22788 228 376000362 419448166 -43447804 X true true 1 1 DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVE BOSTON MA 02215 www.dana-farber.org MA LICENSE NO 2335 X X X A A 1 false false true X X X X X X X X X 18 true false false true X SEE PART V, SECTION C X true 18 true SEE PART V, SECTION C false true X 150. 300. X true true X X X true X SEE PART V, SECTION C X SEE PART V, SECTION C X SEE PART V, SECTION C X X X X X X true X false X X X true X false false Part V, SECTION B, Line 5 IN SEPTEMBER 2019, DANA-FARBER'S BOARD OF TRUSTEES APPROVED THE 2020-2023 CANCER-FOCUSED COMMUNITY HEALTH NEEDS ASSESSMENT (CHNA) AND IMPLEMENTATION PLAN TO ENSURE THAT OUR COLLECTIVE EFFORTS HAVE THE MAXIMUM POSSIBLE IMPACT WITHIN THE INSTITUTE'S PRIORITY NEIGHBORHOODS. DANA-FARBER'S COMMUNITY BENEFITS OFFICE RETAINED HEALTH RESOURCES IN ACTION (HRIA), A NON-PROFIT PUBLIC HEALTH CONSULTANCY ORGANIZATION IN BOSTON, TO UNDERTAKE A COMPREHENSIVE ASSESSMENT OF THE HEALTH NEEDS WITHIN OUR PRIORITY COMMUNITIES, INCLUDING HOW THOSE NEEDS ARE CURRENTLY BEING ADDRESSED AND WHERE THERE ARE OPPORTUNITIES TO ADDRESS THESE NEEDS IN THE FUTURE. DANA-FARBER'S 2020-2023 CANCER CHNA BUILDS OFF OF INFORMATION GATHERED FOR BOSTON'S FIRST LARGE-SCALE COLLABORATIVE CITYWIDE COMMUNITY HEALTH NEEDS ASSESSMENT IN WHICH TARGET NEIGHBORHOODS SUCH AS DORCHESTER, ROXBURY, JAMAICA PLAIN, MISSION HILL, AND MATTAPAN WERE INVESTIGATED THOROUGHLY. THE PURPOSE OF THE CHNA IS TO ADVANCE COMMUNITY EFFORTS AND PRIORITY AREAS BY: ASSESSING CANCER BURDEN IN THE COMMUNITY AS WELL AS ACCESS TO AND AVAILABILITY OF CANCER-RELATED SERVICES; IDENTIFYING KEY AREAS OF SIGNIFICANT COMMUNITY NEED AND VULNERABLE POPULATIONS; EXAMINING THE IMPACT AND ROLE OF SOCIAL DETERMINANTS OF HEALTH; AND FACILITATING THE DEVELOPMENT OF MULTI-YEAR IMPLEMENTATION STRATEGIES TO GUIDE THE HOSPITALS' COMMUNITY HEALTH INITIATIVES AND COMMUNITY INVESTMENTS. IN ADDITION TO IDENTIFYING BROAD HEALTH ISSUES FACING RESIDENTS, THE 2019 CHNA INVESTIGATES THE FULL CONTINUUM OF CANCER CARE; IT EXPLORES DIFFERENT ASPECTS OF CARE FROM INITIAL SCREENING, TO TREATMENT, AND CULMINATES WITH CONSIDERATIONS OF SURVIVORSHIP. THE BOSTON CHNA-CHIP COLLABORATIVE IS A NEW INITIATIVE THAT WAS CREATED AND LAUNCHED BY A NUMBER OF STAKEHOLDERS-COMMUNITY ORGANIZATIONS, HEALTH CENTERS, COMMUNITY DEVELOPMENT CORPORATIONS, HOSPITALS, AND THE BOSTON PUBLIC HEALTH COMMISSION. IT AIMS TO UNDERTAKE THE FIRST LARGE-SCALE COLLABORATIVE CITYWIDE COMMUNITY HEALTH NEEDS ASSESSMENT (BOSTON CHNA) AND COMMUNITY HEALTH IMPROVEMENT PLANNING (BOSTON CHIP) PROCESS. THE GOALS OF THE BOSTON CHNA ARE TO SYSTEMATICALLY IDENTIFY THE HEALTH-RELATED NEEDS, STRENGTHS, AND RESOURCES OF COMMUNITIES TO INFORM FUTURE PLANNING, UNDERSTAND THE CURRENT HEALTH STATUS OF BOSTON OVERALL AND ITS SUB-POPULATIONS WITHIN THEIR SOCIAL CONTEXT, AND MEET REGULATORY REQUIREMENTS FOR A NUMBER OF INSTITUTIONS, ORGANIZATIONS, AND AGENCIES (E.G. IRS REQUIREMENTS FOR NON-PROFIT HOSPITALS, PHAB FOR HEALTH DEPARTMENTS). DURING THE CITYWIDE CHNA, AS A MEMBER OF THE STEERING COMMITTEE AND CO-CHAIR OF THE COMMUNITY ENGAGEMENT WORK GROUP, DANA-FARBER WORKED CLOSELY WITH MEMBERS OF THE BOSTON CHNA/CHIP COLLABORATIVE TO CONDUCT A ROBUST DATA COLLECTION AND ENGAGEMENT PROCESS FOR THE BOSTON CHNA. A CITYWIDE SURVEY WAS ADMINISTERED ONLINE AND IN-PERSON IN 7 LANGUAGES (ENGLISH, SPANISH, PORTUGUESE, HAITIAN CREOLE, CHINESE, VIETNAMESE, AND ARABIC), ENGAGING OVER 90 ORGANIZATIONS AND OVER 2,400 BOSTON RESIDENTS, WITH A FOCUS ON TARGETING HARD TO REACH POPULATIONS NOT TYPICALLY REPRESENTED. A TOTAL OF 13 FOCUS GROUPS WERE CONDUCTED WITH SPECIFIC POPULATIONS, 45 INTERVIEWS WERE HELD WITH ORGANIZATIONAL AND COMMUNITY LEADERS ACROSS VARIOUS SECTORS TO GAUGE THEIR PERCEPTIONS OF COMMUNITY NEEDS, STRENGTHS, AND OPPORTUNITIES. SECTORS REPRESENTED IN THESE INTERVIEWS INCLUDED: PUBLIC HEALTH, HEALTH CARE, HOUSING AND HOMELESSNESS, TRANSPORTATION, COMMUNITY DEVELOPMENT, FAITH, EDUCATION, PUBLIC SAFETY, ENVIRONMENTAL JUSTICE, GOVERNMENT, WORKFORCE DEVELOPMENT, SOCIAL SERVICES, FOOD INSECURITY, AND BUSINESS ORGANIZATIONAL STAFF THAT WORK WITH SPECIFIC POPULATIONS SUCH AS YOUTH, SENIORS, DISABLED, LGBTQ, AND IMMIGRANTS. DURING THE CANCER CHNA, 8 FOCUS GROUPS WERE CONDUCTED WITH ADULT CANCER PATIENTS IN ACTIVE TREATMENT, SURVIVORS, AND CAREGIVERS IN ENGLISH, SPANISH, AND CHINESE. 7 CANCER-SPECIFIC KEY INFORMANT INTERVIEWS WERE HELD WITH CANCER REPRESENTATIVES FROM ROLES RELATED TO PRIMARY CARE, PATIENT NAVIGATION AND ADVOCACY. KEY INFORMANTS REPRESENTED A NUMBER OF SECTORS INCLUDING ACADEMIC RESEARCH, HEALTH CARE, PUBLIC HEALTH, SOCIAL SERVICE, AND CITY GOVERNMENT. DISCUSSIONS EXPLORED PARTICIPANTS' PERCEPTIONS OF THEIR COMMUNITIES, PRIORITY HEALTH CONCERNS, PERCEPTIONS OF CANCER AND RELATED SERVICES ACROSS THE CANCER CONTINUUM (PREVENTION, SCREENING, TREATMENT, SURVIVORSHIP), AND SUGGESTIONS FOR FUTURE SERVICES AND RESOURCES TO ADDRESS THESE ISSUES. THE STRATEGIES AND GOALS OUTLINED IN OUR 2020-2023 CHNA IMPLEMENTATION PLAN ARE A NATURAL CONTINUATION OF THE EFFORTS IDENTIFIED IN OUR 2016-2019 PLAN AND ARE DESIGNED TO ADVANCE AND STRENGTHEN OUR EXISTING COMMUNITY-BASED INITIATIVES WHILE ALSO SEEKING TO ADDRESS THE SOCIAL DETERMINANTS OF HEALTH THROUGH COLLABORATIVE PARTNERSHIPS. PART V, SECTION B, LINE 7A DFCI'S COMMUNITY HEALTH NEEDS ASSESSMENT REPORT IS AVAILABLE ON THE DFCI WEBSITE. https://www.dana-farber.org/uploadedFiles/Pages/About_Us/Community_Outreac h/chna-report-approved-9.11.19.pdf PART V, SECTION B, LINE 10A DFCI'S IMPLEMENTATION STRATEGY IS AVAILABLE ON THE DFCI WEBSITE. https://www.dana-farber.org/uploadedFiles/Pages/About_Us/Community_Outreac h/chna-chip-board-approved-12.23.2019.pdf PART V, SECTION B, LINE 11 DANA-FARBER CANCER INSTITUTE ADDRESSED ALL THE NEEDS IDENTIFIED IN THE COMMUNITY HEALTH NEEDS ASSESSMENT AND THE ACCOMPANYING IMPLEMENTATION PLAN. A FULL DESCRIPTION OF OUR PROGRAMS IS AVAILABLE ON OUR WEBSITE BOTH IN THE COMMUNITY HEALTH NEEDS ASSESSMENT REPORT AND IN THE COMMUNITY HEALTH IMPLEMENTATION PLAN. WHILE OUR EXPERTISE AS A COMPREHENSIVE CANCER CENTER LEADS US TO FOCUS LARGELY ON REDUCING CANCER INCIDENCE AND MORTALITY AMONG MEDICALLY UNDERSERVED POPULATIONS THROUGH OUR CLINICAL COMMUNITY SCREENING AND OUTREACH PROGRAMS THAT INCLUDE MOBILE MAMMOGRAPHY AND BREAST HEALTH EDUCATION, SKIN CANCER EDUCATION AND SCREENING, HPV EDUCATION AND VACCINATION, TOBACCO CESSATION AND INCREASING AWARENESS ABOUT SURVIVORSHIP IN COMMUNITIES OF COLOR, WE RECOGNIZE THAT OUR PRIORITY NEIGHBORHOODS ARE ALSO DEALING DISPROPORTIONATELY WITH CHALLENGING SITUATIONS RELATED TO SOCIAL AND ECONOMIC FACTORS SUCH AS LIMITED EMPLOYMENT OPPORTUNITIES, SUBSTANCE ABUSE AND OPIOID ADDICTION, LOW EDUCATION LEVELS, LACK OF AFFORDABLE HOUSING, AND COMMUNITY VIOLENCE, AMONG OTHERS. WE WORK ON THESE BROADER ISSUES BY ADVOCATING AND BY PARTNERING WITH LOCAL COALITIONS AND COMMUNITY BASED ORGANIZATIONS SUCH AS BOSTON ALLIANCE FOR COMMUNITY HEALTH AND MEMBER ORGANIZATIONS. PART V, SECTION B, LINE 16A DFCI'S FINANCIAL ASSISTANCE POLICY IS AVAILABLE ON THE DFCI WEBSITE. HTTPS://WWW.DANA-FARBER.ORG/UPLOADEDFILES/PAGES/FOR_PATIENTS_AND_FAMILIES/ CARE_AND_TREATMENT/SUPPORT_SERVICES_AND_AMENITIES/FINANCIAL-ASSISTANCE-FUL L-POLICY.PDF PART V, SECTION B, LINE 16B DFCI'S FINANCIAL ASSISTANCE POLICY APPLICATION FORM IS AVAILABLE ON THE DFCI WEBSITE. HTTPS://WWW.DANA-FARBER.ORG/UPLOADEDFILES/PAGES/FOR_PATIENTS_AND_FAMILIES/ CARE_AND_TREATMENT/SUPPORT_SERVICES_AND_AMENITIES/FINANCIAL-ASSISTANCE-APP LICATION.PDF PART V, SECTION B, LINE 16C DFCI'S FINANCIAL ASSISTANCE POLICY PLAIN LANGUAGE SUMMARY IS AVAILABLE ON THE DFCI WEBSITE. HTTPS://WWW.DANA-FARBER.ORG/UPLOADEDFILES/PAGES/FOR_PATIENTS_AND_FAMILIES/ CARE_AND_TREATMENT/SUPPORT_SERVICES_AND_AMENITIES/FINANCIAL-ASSISTANCE-SUM MARY.PDF PART V, SECTION B, LINE 22 DEPENDING ON A PATIENT'S FINANCIAL SITUATION, FAP-ELIGIBLE PATIENTS WERE CHARGED BETWEEN 0% TO 30% OF BILLED CHARGES, WHICH WAS NOT MORE THAN THE AGB. IN FY21, DFCI DETERMINED AGB ON AN ANNUAL BASIS USING THE "LOOK-BACK METHOD," DESCRIBED UNDER TREASURY REGULATION SECTION 1.501(R)-5(B)(1). SPECIFICALLY, DFCI'S ANNUAL AGB PERCENTAGE WAS EQUAL TO THE SUM OF ALL GROSS CHARGES DURING THE PRIOR FISCAL YEAR DIVIDED BY CLAIMS PAID IN CONNECTION WITH THOSE CHARGES. FOR PURPOSES OF THE AGB CALCULATION, CLAIMS PAID INCLUDED CLAIMS FOR EMERGENCY AND MEDICALLY NECESSARY CARE PAID BY BOTH MEDICARE FEE-FOR-SERVICE AND ALL PRIVATE HEALTH INSURERS AS PRIMARY PAYERS, TOGETHER WITH ANY ASSOCIATED PORTIONS OF THESE CLAIMS PAID BY MEDICARE BENEFICIARIES OR INSURED INDIVIDUALS IN THE FORM OF CO-PAYMENTS, CO-INSURANCE OR DEDUCTIBLES. 9 DFBWCC AT SOUTH SHORE HOSPITAL 101 COLUMBIAN STREET SOUTH WEYMOUTH MA 02190 SATELLITE DFBWCC AT MILFORD REGIONAL MED CNTR 20 PROSPECT STREET MILFORD MA 01757 SATELLITE DFCI - CHESTNUT HILL 300 BOYLSTON STREET NEWTON MA 02459 SATELLITE DFCI - MERRIMACK VALLEY 5 BRANCH STREET METHUEN MA 01844 SATELLITE DFNH ONCOLOGY-HEMATOLOGY ELLIOTT MED CENTER 40 BUTTRICK RD LONDONDERRY NH 03053 SATELLITE DFCI AT ST ELIZABETH'S MEDICAL CNTR CUSHING PAVILION 736 CAMBRIDGE STR BRIGHTON MA 02135 SATELLITE DFCI - LIBBEY PARK 51 PERFORMANCE DRIVE WEYMOUTH MA 02189 SATELLITE DFCI - MOBILE MAMMOGRAPHY SERVICE 450 BROOKLINE AVENUE BOSTON MA 02215 SATELLITE DFCI - WHITTIER STREET HEALTH CENTER 1290 Tremont Street Roxbury MA 02120 SATELLITE Part I, Line 3c IN ADDITION TO DETERMINING ELIGIBILITY FOR DISCOUNTED CARE BASED ON FAMILY INCOME, DANA-FARBER CANCER INSTITUTE, INC. (DFCI) OFFERS ASSISTANCE TO PATIENTS WHO HAVE EXCESSIVE MEDICAL BILLS (EXCEEDING 30-40% OF FAMILY INCOME). Part I, Line 6a THE COMMUNITY BENEFIT REPORT WAS COMPLETED BY DFCI AND IS ANNUALLY PROVIDED TO THE MASSACHUSETTS ATTORNEY GENERAL'S OFFICE, WHERE IT IS THEN MADE AVAILABLE TO THE PUBLIC ON ITS WEBSITE. Part I, Line 7 DFCI'S STATE COST REPORT WAS USED TO DEVELOP THE INSTITUTE'S COST TO CHARGE RATIO THAT WAS APPLIED TO CHARITY CARE CHARGES TO DETERMINE THE COST OF FINANCIAL ASSISTANCE (LINE 7A). LINE 7B REFLECTS THE SPECIFIC LOSS INCURRED FOR THE INSTITUTE'S MEDICAID ACTIVITY. THE INSTITUTE IS A PREEMINENT PROVIDER OF HEALTH TRAINING TO HEALTH PROFESSIONALS WHO DESIRE TRAINING IN THE SKILLS NECESSARY TO TREAT CANCER PATIENTS. THE INSTITUTE TRAINS PHYSICIANS, SCIENTISTS, MEDICAL STUDENTS, AND INDIVIDUALS LOOKING TO CREATE A CAREER IN THE FIELD OF CANCER. THE AMOUNT REPORTED AS HEALTH TRAINING REPRESENT COSTS IN EXCESS OF AMOUNTS REIMBURSED BY THIRD PARTY PAYERS SUCH AS TRAINING GRANT REVENUES AND DIRECT MEDICAL EDUCATION PAYMENTS FROM THE MEDICARE PROGRAM. DEPARTMENT LEADERS SUBMIT EXPENDITURES TO COMMUNITY BENEFITS ALONG WITH A DESCRIPTION OF THE SERVICES PROVIDED TO MEDICALLY UNDERSERVED POPULATIONS. LINE 7F EXPENDITURES ARE REVIEWED BY LEADERSHIP AND IN PARTNERSHIP WITH DFCI'S OFFICE OF FINANCE, THE EXPENDITURES ARE APPROVED. THE AMOUNTS ARE CAPTURED IN THREE BUCKETS - CB EXPENDITURES (ALL PROGRAMS); LEVERAGED FUNDS (THOSE FUNDS SUPPORTED IN FULL OR PART THROUGH GRANTS/DONATIONS) AND COMMUNITY SPONSORSHIPS. Part II, Line 1 PHYSICAL IMPROVEMENTS AND HOUSING - DFCI PROVIDES A LIMITED NUMBER OF LOW-COST ROOMS THAT SERVE AS A HOME AWAY FROM HOME FOR ONCOLOGY PATIENTS AND THEIR FAMILIES WHILE THEY ARE RECEIVING TREATMENT. Part II, Line 8 WORKFORCE DEVELOPMENT - TO ENCOURAGE UNDERREPRESENTED STUDENTS OF COLOR TO EXPLORE AND PURSUE CAREERS IN HEALTH AND SCIENCE, DANA-FARBER MAINTAINS EDUCATIONAL PARTNERSHIPS WITH BOSTON AREA HIGH SCHOOLS AND COLLEGES. DURING ACADEMIC YEAR 2021, 21 STUDENTS PARTICIPATED IN A COLLEGE AND CAREER READINESS TRAINING PROGRAM. AN ADDITIONAL 54 STUDENTS WERE ENROLLED DURING THE 2021 SUMMER JOBS PROGRAM AT DANA-FARBER. ELIGIBLE STUDENTS EITHER ATTENDED OR GRADUATED FROM BOSTON PUBLIC SCHOOLS. DURING THE SUMMER PROGRAM, STUDENTS INTERNED THROUGH A HYBRID PROGRAM, SOME INTERNS SERVED DEPARTMENTS REMOTELY AND OTHERS WERE ON-SITE AT DANA-FARBER. ALL PARTICIPATED IN COLLEGE TOURS AND CAREER READINESS WORKSHOPS THAT WERE HELD VIRTUALLY. PART III, SECTION A, LINES 2 & 3 IN CALCULATING BAD DEBT EXPENSE, DFCI USES A COMBINATION OF ACTUAL BAD DEBT WRITE OFFS AND HISTORICAL BAD DEBT FACTORS IN DETERMINING WHICH CURRENT ACCOUNTS RECEIVABLE ARE NOT LIKELY TO BE COLLECTED. IN FY21, DFCI RELEASED THE ADDITIONAL RESERVE FOR SOME INTERNATIONAL ACCOUNTS THAT WERE DEEMED NOT LIKELY TO BE COLLECTED. ADDITIONALLY, DFCI DETERMINES THE AMOUNT OF BAD DEBT ATTRIBUTABLE TO INDIVIDUALS WHO ARE ELIGIBLE FOR FINANCIAL ASSISTANCE BASED ON A HISTORICAL ESTIMATE OF THE PERCENTAGE OF PATIENTS THAT HAVE QUALIFIED FOR FINANCIAL ASSISTANCE, WHICH IS APPLIED AGAINST TOTAL BAD DEBT. PART III, SECTION A, LINE 4 CONSISTENT WITH THE INSTITUTE'S MISSION, CARE IS PROVIDED TO PATIENTS REGARDLESS OF THEIR ABILITY TO PAY. THE INSTITUTE HAS DETERMINED IT HAS PROVIDED IMPLICIT PRICE CONCESSIONS TO UNINSURED PATIENTS AND PATIENTS WITH OTHER UNINSURED BALANCES (E.G. COPAYS AND DEDUCTIBLES). THE IMPLICIT PRICE CONCESSIONS INCLUDED IN ESTIMATING THE TRANSACTION PRICE REPRESENT THE DIFFERENCE BETWEEN AMOUNTS BILLED TO PATIENTS AND THE AMOUNTS THE INSTITUTE EXPECTS TO COLLECT BASED ON ITS COLLECTION HISTORY WITH THOSE PATIENTS. PATIENTS WHO MEET THE INSTITUTE'S CRITERIA FOR CHARITY CARE ARE PROVIDED CARE WITHOUT CHARGE OR AT AMOUNTS LESS THAN ESTABLISHED RATES. THE INSTIUTE HAS DETERMINED THAT IT HAS PROVIDED SUFFICIENT IMPLICIT PRICE CONCESSIONS FOR THESE ACCOUNTS. PRICE CONCESSIONS, INCLUDING CHARITY CARE, ARE NOT REPORTED AS REVENUE. PART III, SECTION B, LINE 8 THE MEDICARE COST ON LINE 6 COMES FROM THE MEDICARE COST REPORT AND IS BASED ON MEDICARE'S COST FINDING PRINCIPLES AND METHODOLOGIES. WE STRONGLY BELIEVE THAT THE ENTIRE AMOUNT OF THE SHORTFALL OF $43,447,804 SHOULD BE TREATED AS A COMMUNITY BENEFIT AS THIS REPRESENTS THE INSTITUTE'S COMMITMENT TO THE ELDERLY AND DISABLED COMMUNITY BY PROVIDING SERVICES THAT ARE NOT REIMBURSED. PART III, SECTION C, LINE 9B WITHIN DFCI'S CREDIT AND COLLECTIONS POLICY THERE ARE PROVISIONS THAT DESCRIBE COLLECTION PRACTICES TO BE FOLLOWED FOR PATIENTS WHO ARE KNOWN TO QUALIFY FOR CHARITY CARE OR FINANCIAL ASSISTANCE IN ACCORDANCE WITH FEDERAL AND MASSACHUSETTS LAW. Part V, Sections A & D DFCI'S MAIN CAMPUS IS AT 450 BROOKLINE AVE., BOSTON, MA, 02115. DFCI'S SATELLITE LOCATIONS (BELOW) EACH OPERATE UNDER THE SAME HOSPITAL LICENSE. DANA-FARBER/BRIGHAM AND WOMEN'S CANCER CENTER AT MILFORD HOSPITAL, 20 PROSPECT STREET, MILFORD, MA 01757, DANA-FARBER/BRIGHAM AND WOMEN'S CANCER CENTER AT SOUTH SHORE HOSPITAL, 101 COLUMBIAN STREET, SOUTH WEYMOUTH, MA 02190, DANA-FARBER AT ST. ELIZABETH'S MEDICAL CENTER, 736 CAMBRIDGE STREET, CUSHING PAVILION, 5TH FLOOR, BRIGHTON, MA 02135, DANA-FARBER CANCER INSTITUTE CHESTNUT HILL, 300 BOYLSTON STREET, NEWTON, MA 02459, DANA-FARBER CANCER INSTITUTE - MERRIMACK VALLEY, 5 BRANCH STREET, METHUEN, MA 01844, DANA-FARBER CANCER INSTITUTE - LIBBEY PARK, 51 PERFORMANCE DRIVE, WEYMOUTH, MA 02189, DANA-FARBER CANCER INSTITUTE - MOBILE MAMMOGRAPHY SERVICE, 450 BROOKLINE AVENUE, BOSTON, MA 02215, DANA-FARBER CANCER INSTITUTE - WHITTIER STREET HEALTH CENTER, 1290 TREMONT STREET, ROXBURY, MA 02120. Dana-Farber/New Hampshire Oncology Hematology also operates a clinical location at 40 Buttrick Road, Suite B, Londonderry, NH. Part VI, Line 2 DANA-FARBER CANCER INSTITUTE CONTINUOUSLY ASSESSES THE COMMUNITY NEEDS THROUGH OUR PARTICIPATION IN COMMUNITY COALITIONS, TASK FORCES, WORKING GROUPS, AND DIRECT COMMUNICATION WITH THE COMMUNITY RESIDENTS THAT SERVE ON OUR EXTERNAL ADVISORY COMMITTEE AND ON OUR PATIENT AND FAMILY ADVISORY BOARD. A FULL DESCRIPTION OF OUR COMMUNITY ENGAGEMENT PROCESS CAN BE FOUND ON OUR WEBSITE BOTH IN THE COMMUNITY HEALTH NEEDS ASSESSMENT REPORT AND IN THE COMMUNITY HEALTH IMPLEMENTATION PLAN. Part VI, Line 3 DFCI IS COMMITTED TO OFFERING FINANCIAL ASSISTANCE TO ELIGIBLE PATIENTS WHO DO NOT HAVE THE ABILITY TO PAY FOR THEIR MEDICAL SERVICES IN WHOLE OR IN PART. IN ORDER TO ACCOMPLISH THIS CHARITABLE GOAL, DFCI WIDELY PUBLICIZES ITS PATIENT FINANCIAL ASSISTANCE (PFA) POLICY WITHIN ITS FACILITIES, IN DIRECT COMMUNICATIONS WITH PATIENTS AND IN THE COMMUNITIES THAT IT SERVICES, PARTICULARLY IN THE COMMUNITIES WITH THE GREATEST UNMET HEALTH NEEDS. THE PFA POLICY, A PLAIN LANGUAGE PFA SUMMARY, AND THE PFA APPLICATION ARE POSTED ON DFCI'S WEBSITE IN ENGLISH AND SPANISH. IN ADDITION, INFORMATION ABOUT THE PFA IS PROVIDED TO ALL PATIENTS AT REGISTRATION AND/OR ADMISSION, AND IS AVAILABLE UPON REQUEST, WITHOUT CHARGE, THROUGH A DFCI FINANCIAL COUNSELOR, CUSTOMER SERVICE REPRESENTATIVE, OR BY MAIL. FOLLOWING CARE, ALL BILLING STATEMENTS SENT TO A PATIENT INDICATE HOW THE PATIENT CAN OBTAIN INFORMATION ABOUT THE PFA POLICY. IN COLLABORATION WITH DFCI'S COMMUNITY PARTNERS, INFORMATION ABOUT THE FAP IS SHARED WITH RESIDENTS OF DFCI'S PRIORITY NEIGHBORHOODS. EFFORTS TO NOTIFY COMMUNITY MEMBERS MOST LIKELY TO REQUIRE ASSISTANCE INCLUDE DISTRIBUTING PLAIN LANGUAGE SUMMARIES OF THIS POLICY TO LOCAL COMMUNITY HEALTH CENTERS AND OTHER NON-PROFIT ORGANIZATIONS. Part VI, Line 4 DFCI SERVES THE COMMUNITY OF EASTERN MASSACHUSETTS AND NEW ENGLAND, INCLUDING THE COMMUNITIES SURROUNDING ITS PRIMARY LOCATION IN BOSTON AND ITS SATELLITE LOCATIONS IN MILFORD, WEYMOUTH, BRIGHTON, NEWTON, METHUEN, AND LONDONDERRY (NH). DFCI'S COMMUNITY INCLUDES ADULTS AND CHILDREN WITH CANCER OR AT RISK OF DEVELOPING CANCER, AND THEIR FAMILIES. DFCI FOCUSES ITS COMMUNITY OUTREACH EFFORTS ON ITS PRIORITY BOSTON NEIGHBORHOODS OF ROXBURY, MISSION HILL, DORCHESTER, MATTAPAN, AND JAMAICA PLAIN (WHICH COLLECTIVELY COMPRISE 39% OF BOSTON'S OVERALL POPULATION). TWO OF BOSTON'S MOST POPULATED NEIGHBORHOODS ARE DFCI'S PRIORITY NEIGHBORHOODS - DORCHESTER WITH 122,598 RESIDENTS, FOLLOWED BY ROXBURY WITH 49,028. WHITE RESIDENTS NOW MAKE UP LESS THAN HALF OF THE CITY'S RACIAL AND ETHNIC COMPOSITION (46%). BLACK OR AFRICAN AMERICAN RESIDENTS WERE THE SECOND LARGEST RACIAL AND ETHNIC GROUP (23%), FOLLOWED BY HISPANICS (18%), AND ASIANS (9%). THERE IS SUBSTANTIAL VARIATION IN THE RACIAL AND ETHNIC DIVERSITY BY DFCI PRIORITY NEIGHBORHOOD, WITH NEARLY THREE-QUARTERS OF MATTAPAN RESIDENTS AND HALF OF ROXBURY RESIDENTS IDENTIFYING AS BLACK OR AFRICAN AMERICAN. AMONG DFCI PRIORITY NEIGHBORHOODS, ROXBURY AND JAMAICA PLAIN HAVE THE LARGEST HISPANIC POPULATIONS WITH 29% AND 24% RESPECTIVELY, WHILE MISSION HILL AND DORCHESTER HAVE THE LARGEST ASIAN POPULATIONS AMONG THE PRIORITY NEIGHBORHOODS WITH 14% AND 10% RESPECTIVELY. THE MEDIAN INCOMES OF DFCI'S PRIORITY COMMUNITIES ARE GENERALLY MUCH LOWER THAN BOSTON OVERALL, WITH ROXBURY AT A MEDIAN INCOME OF $25,254, MISSION HILL AT $35,020, AND MATTAPAN AT $42,206. MANY OF DFCI'S PRIORITY NEIGHBORHOODS, ROXBURY AND MATTAPAN, ARE MORE LIKELY TO HAVE A GREATER POPULATION AT THE LOWER END OF THE INCOME SPECTRUM. RESIDENTS IN DFCI'S PRIORITY NEIGHBORHOODS APPEAR TO EXPERIENCE HIGHER RATES OF POVERTY THAN BOSTON OVERALL. FEMALE HEADED HOUSEHOLDS ARE ESPECIALLY VULNERABLE, WITH 45% OF ROXBURY FEMALE-HEADED HOUSEHOLDS LIVING BELOW THE POVERTY LINE. DESPITE ITS STATEWIDE REACH AND SERVICES PROVIDED THROUGH OUR SATELLITE OPERATIONS IN WEYMOUTH, MILFORD, NEWTON, METHUEN, AND ALLSTON/BRIGHTON, DANA-FARBER'S PRIORITIZATION OF THESE FIVE NEIGHBORHOODS WITHIN ITS LOCAL SERVICE AREA REFLECTS A COMMITMENT TO REDUCING DISPARITIES IN CANCER CARE AND IMPROVING THE HEALTH AND WELL-BEING OF NEIGHBORHOOD RESIDENTS. THROUGH OUR COLLABORATIVE APPROACH, THE SATELLITE LOCATIONS HAVE AGREED TO LEVERAGE EACH OTHER'S CANCER CONTROL EXPERTISE TO EXPAND AND STRENGTHEN OUR PROGRAMS SUCH AS BRINGING CANCER PREVENTION EFFORTS IN SPANISH TO THE WEYMOUTH AREA. THE ALLSTON/BRIGHTON SATELLITES HAVE ALSO MUTUALLY AGREED TO CONTINUE TO WORK TOGETHER TO STRENGTHEN MAMMOGRAPHY SCREENING RATES THROUGH OUR PARTNERSHIP WITH THE LOCAL COMMUNITY HEALTH CENTER AND TO EXPLORE OTHER OPPORTUNITIES TO HAVE GREATER IMPACT ON THE HEALTH AND WELL-BEING OF LOCAL RESIDENTS. DANA-FARBER ALSO AIMS TO PRIORITIZE POPULATIONS DISPROPORTIONATELY IMPACTED BY CANCER, INCLUDING DIVERSE RACIAL AND ETHNIC POPULATIONS, INDIVIDUALS FROM LOW SOCIOECONOMIC BACKGROUNDS, AND IMMIGRANTS. BASED ON THE CHNA DATA, THE POPULATIONS ABOVE APPEAR TO HAVE DISPROPORTIONATELY HIGHER LEVELS OF DISEASE RISK AND BURDEN, WARRANTING INCREASED ATTENTION. Part VI, Line 5 DANA-FARBER'S 2020-2023 COMMUNITY HEALTH NEEDS ASSESSMENT AND IMPLEMENTATION PLAN PROVIDE A ROBUST DESCRIPTION OF OUR COMPREHENSIVE CANCER CONTROL PROGRAMS AND SERVICES. THE REPORT ALSO PROVIDES A SUMMARY OF ACCOMPLISHMENTS FROM OUR LAST NEEDS ASSESSMENT AND SETS FORTH OUR COMMITMENT TO ADDRESSING THE NEW OPPORTUNITIES TO REDUCE THE CANCER BURDEN IN MEDICALLY UNDERSERVED COMMUNITIES IN BOSTON. THE REPORTS CAN BE FOUND USING THE FOLLOWING LINKS: COMMUNITY HEALTH NEEDS ASSESSMENT - https://www.dana-farber.org/uploadedFiles/Pages/About_Us/Community_Outreac h/chna-report-approved-9.11.19.pdf IMPLEMENTATION PLAN - https://www.dana-farber.org/uploadedFiles/Pages/About_Us/Community_Outreac h/chna-chip-board-approved-12.23.2019.pdf IN ADDITION, DFCI FURTHERS ITS EXEMPT PURPOSE BY PROMOTING THE HEALTH OF THE COMMUNITY THROUGH DEVOTING THE VAST MAJORITY OF ITS SURPLUS FUNDS TO INSTITUTIONAL SUPPORTED RESEARCH (135 MILLION), BY PROVIDING FINANCIAL ASSISTANCE TO PATIENTS UNABLE TO AFFORD CARE AND BY MAINTAINING A COMMUNITY BOARD. PART VI, LINE 7 DFCI FILES ITS COMMUNITY BENEFIT REPORT WITH THE STATE OF MASSACHUSETTS. true AMERICAN CANCER SOCIETY 250 Williams St Atlanta GA 30303 131788491 501(c)(3) 20000 CANCER RES AND DEVLP BOSTON PRIVATE INDUSTRY COUNCIL 2 Oliver St Boston MA 02109 042676661 501(c)(3) 10000 CANCER RES AND DEVLP BOSTON PUBLIC HEALTH COMMISSION 1010 Massachusetts Ave BOSTON MA 02118 043316655 115 10000 COMMUNITY SUPPORT City of Boston City Hall Plaza Boston MA 02114 046001380 115 1533623 COMMUNITY SUPPORT Friends of Dana-Farber 450 Brookline Ave Boston MA 02215 371613621 501(c)(3) 50000 CANCER RES AND DEVLP HARVARD UNIVERSITY 60 Oxford Street CAMBRIDGE MA 02138 042103580 501(c)(3) 1333475 CANCER RES AND DEVLP INTERNATIONAL SOCIETY OF STEM CELL 5215 Old Orchard Rd NO 270 SKOKIE IL 60077 364491158 501(c)(3) 10000 CANCER RES AND DEVLP LEUKEMIA & LYMPHOMA SOCIETY INC 1311 MAMARONECK AVE WHITE PLANES NY 10605 135644916 501(c)(3) 40000 CANCER RES AND DEVLP Madison Park Development Corporation 184 Dudley St Roxbury MA 02119 237164223 501(c)(3) 21250 COMMUNITY SUPPORT PROSTATE HEALTH EDUCATION NETWORK INC 500 Victory Rd 4th FL Quincy MA 02453 331042404 501(c)(3) 30000 CANCER RES AND DEVLP RESEARCH AMERICA 241 18th St So NO 501 Arlington VA 22202 521609875 501(c)(3) 8600 CANCER RES AND DEVLP SWIM ACROSS AMERICA INC 8508 Park Road NO 389 charlotte NC 28210 223248256 501(c)(3) 15000 CANCER RES AND DEVLP UNITED WAY OF MASSACHUSETTS BAY 51 Sleeper St Boston MA 02210 042382233 501(c)(3) 10000 Community Support Whittier Street Health Center 1125 TREMONT STREET ROXBURY MA 02120 042619517 501(c)(3) 144270 COMMUNITY SUPPORT 12 2 Patient Assistance 645 619159 Patient Assistance 2788 1422185 FMV ASST LIVING & TRAVEL Schedule I, Part I, Line 2 PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS ALL GRANTS AND DONATIONS TO DOMESTIC ORGANIZATIONS WERE GIVEN TO 501(C)(3) ORGANIZATIONS TO FULFILL THEIR MISSIONS, OR GOVERNMENT ENTITIES. ALL GRANT FUNDS TO INDIVIDUALS WERE PROVIDED BASED ON EITHER (AND ONLY) 1) MEANS-TESTED FINANCIAL NEED, OR 2) CLINICALLY-DETERMINED IMPROVEMENT TO QUALITY-OF-LIFE. X X X X X true true false false false false false true false Glimcher Laurie H MD Trustee, President and CEO 1220120 0 422902 0 81203 0 285781 0 16612 0 2026618 0 0 0 Benz Edward J JR MD President and CEO Emeritus 565636 0 400 0 567346 0 40140 0 17287 0 1190809 0 0 0 Reney Michael L CFO and Asst. Treasurer 685477 0 117535 0 26029 0 40140 0 3754 0 872935 0 0 0 Hahn William MD PHD COO & EVP 575714 0 210752 0 12566 0 40140 0 3320 0 842492 0 0 0 Terwilliger James FORMER COO & EVP 354604 0 82716 0 377877 0 0 0 24858 0 840055 0 0 0 Bunnell Craig A MD CHIEF MEDICAL OFFICER 637037 0 115977 0 23201 0 40140 0 6303 0 822658 0 0 0 Winer Eric MD Chief of Div of WMNS CANCERS 583287 0 116219 0 60678 0 40140 0 14628 0 814952 0 0 0 Soiffer Robert MD Chief of Hemotologic Malig. 568655 0 130478 0 23386 0 40138 0 19811 0 782468 0 0 0 DUVAL MELANY SVP OF DEVELOPMENT 615260 0 80122 0 2421 0 56015 0 17704 0 771522 0 0 0 Constantine Michael MD Milford Med Dir-Hematol Onc 640094 0 35073 0 25816 0 25890 0 35247 0 762120 0 0 0 Johnson Bruce MD CHIEF CL RES OFF(END 9/1/21) 546586 0 104249 0 28696 0 38623 0 22916 0 741070 0 0 0 Boskey Richard S ESQ ASST. SEC. & GC (END 12/14/20) 536204 0 93760 0 22055 0 40140 0 28173 0 720332 0 0 0 Griffin James D MD PROFESSOR OF MEDICINE 612057 0 400 0 29707 0 40140 0 25258 0 707562 0 0 0 Rollins Barrett J MD PHD SNR ADVISOR TO PRESIDENT & CEO 474403 0 101475 0 14997 0 40140 0 20341 0 651356 0 0 0 Megdal Maria SVP of Institute Operations 446318 0 76080 0 5142 0 40140 0 18452 0 586132 0 0 0 Stone Richard M MD PROFESSOR OF MEDICINE 438387 0 39937 0 16452 0 40140 0 28301 0 563217 0 0 0 Liebow Elizabeth CHIEF STRATEGY OFFICER 393573 0 69200 0 1518 0 37115 0 28932 0 530338 0 0 0 Memmott Drew SVP RESEARCH ADMINISTRATION 394350 0 68921 0 1512 0 36936 0 26102 0 527821 0 0 0 Meyerhardt Jeffrey CHIEF CL RES OFF(as of 9/1/21) 400241 0 20326 0 7659 0 38215 0 35386 0 501827 0 0 0 Haigis Kevin Chief Scientific Officer 377414 0 80400 0 1854 0 0 0 3588 0 463256 0 0 0 Gettleman Wendy VP of Facilities MGMT & RE 317523 0 28305 0 2259 0 29004 0 36133 0 413224 0 0 0 Bartel Sylvia RPH MHP VP of Pharmacy Services 294931 0 28858 0 3257 0 27023 0 37919 0 391988 0 0 0 Ebert Benjamin MD PHD Chair of Medical Oncology 90547 0 400 0 109453 0 6379 0 1932 0 208711 0 0 0 SCHEDULE J, PART I, LINE 4A JAMES TERWILLIGER RECEIVED SEVERANCE PAYMENTS IN THE AMOUNT OF $360,500. THIS AMOUNT IS INCLUDED ON SCHEDULE J, PART II, COLUMN B (III). SCHEDULE J, PART I, LINE 4B The following individuals participate in 457(f) plans established by DFCI; taxable amounts are included in reportable compensation in schedule J, Part II, column (B)(iii): GLIMCHER, LAURIE, MD 66,725 BENZ, EDWARD J. JR., MD 554,876 RENEY, MICHAEL 21,127 HAHN, WILLIAM, MD, PHD 8,456 BUNNELL, CRAIG A. MD 17,750 WINER, ERIC, MD 13,496 SOIFFER, ROBERT, MD 12,170 CONSTANTINE, MICHAEL, MD 18,490 JOHNSON, BRUCE MD 10,339 BOSKEY, RICHARD S., ESQ 9,608 GRIFFIN, JAMES D., MD 16,000 ROLLINS, BARRETT J., MD, PHD 4,776 MEGDAL, MARIA 1,875 STONE, RICHARD M., MD 1,518 SCHEDULE J, PART I, LINE 7 DURING THE YEAR, THE CEO, COO, CFO, GENERAL COUNSEL AND CERTAIN KEY EMPLOYEES AND HIGHEST COMPENSATED EMPLOYEES WERE ELIGIBLE TO RECEIVE AN INCENTIVE PAYMENT, A PORTION OF WHICH HAS A NON-FIXED PAYMENT PAYABLE AT THE DISCRETION OF THE CEO AND IN THE CASE OF THE CEO, THE BOARD OF TRUSTEES, IF THE ORGANIZATION MEETS CERTAIN FINANCIAL PERFORMANCE GOALS. THE MAXIMUM NON-FIXED PORTION OF THESE INCENTIVE PAYMENTS IS BETWEEN 8% (CEO - 40% MAX, OF THAT 32% TEAM, 8% INDIVIDUAL) AND 4% (SVP - 20% MAX, OF THAT 16% TEAM AND 4% INDIVIDUAL; VP - 10% MAX, OF THAT 6% TEAM AND 4% INDIVIDUAL; and (EVP-30% MAX, OF THAT 24% TEAM AND 6% INDIVIDUAL). OTHER REPORTABLE COMPENSATION INCLUDES CURRENT YEAR VESTING AMOUNTS IN DANA-FARBER INSTITUTE'S SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN. A Massachusetts Development Finance Agency 043431814 2015-08-03 92500000 See Part VI false false false B Massachusetts Development Finance Agency 043431814 5758XNZ00 2016-06-23 281786480 See Part VI false false false C Massachusetts Development Finance Agency 043431814 57584YVC0 2019-09-03 60255238 See Part VI false false false D MASSACHUSETTS DEVELOPMENT FINANCE AGENCY 043431814 2021-07-28 57500000 See Part VI false false false A 0 0 92500000 0 0 0 0 0 0 0 92500000 0 2015 true false true true B 0 0 282863767 0 1077287 0 2486701 0 0 279299779 0 0 2019 false false true true C 0 0 60255238 0 0 0 1163957 0 0 0 59091281 0 2019 true false true true D 0 0 57500000 0 0 0 0 0 0 0 57500000 0 2021 true false true true A false false true true true true 0.00000 0.00000 0.00000 false false 0.00000 false true B false false false true true 0.00000 0.00000 0.00000 false false 0.00000 false true C false false true true true true 0.00000 0.00000 0.00000 false false false true D false false true true true true 0.00000 0.00000 0.00000 false false 0.00000 false true A false false false true true true Morgan Stanley 39.8 false false false 0 false true B false false false true false false 0 false 0 false true C false false false true false false 0 false 0 false true D false false true false true true MORGAN STANLEY 39.8 false false false 0 false true A true B true C true D true Schedule K, PART I (BOND ISSUES): A (F) DESCRIPTION OF PURPOSE: THE BOND ISSUE WAS USED TO REFUND SERIES L-1 BONDS ISSUED ON 5/22/2008. B (F) DESCRIPTION OF PURPOSE: THE BOND ISSUE WAS USED TO PARTIALLY COVER THE ACQUISITION AND FIT-OUT OF RESEARCH SPACE AND VIVARIUM AT THE LONGWOOD CENTER; TO PARTIALLY COVER THE REPLACEMENT OF HVAC SYSTEM AT THE SMITH BUILDING; TO COVER THE RELOCATION TO, RECONSTRUCTION AND EQUIPPING OF THE INSTITUTE'S CELL MANIPULATION CORE FACILITY; AND TO COVER THE COSTS OF BOND ISSUANCE AND INTEREST DURING THE CONSTRUCTION PERIOD AS WELL AS OTHER CAPITAL PROJECTS. C (F) DESCRIPTION OF PURPOSE: THE BOND ISSUE WAS USED TO REFUND SERIES K BONDS ISSUED ON 5/22/2008. D (F) DESCRIPTION OF PURPOSE: THE BOND ISSUE WAS USED TO REFUND SERIES L-2A BONDS ISSUED ON 7/2/2012. E (F) DESCRIPTION OF PURPOSE: THE BOND ISSUE WAS USED TO REFUND SERIES L-2B BONDS ISSUED ON 7/2/2012. Schedule K, PART II (PROCEEDS): B 3 THE TOTAL PROCEEDS OF $282,863,767 INCLUDE INVESTMENT EARNINGS IN THE AMOUNT OF $1,077,287. Schedule K, PART IV (ARBITRAGE): A 2(c) Did the following apply "No rebate due" - rebate calculation was performed in November 2020 B 2(c) Did the following apply "No rebate due" - rebate calculation was performed in November 2020 C 2(c) Did the following apply "No rebate due" - rebate calculation was performed in November 2020 D 2 (B) This issuance was refunded in 2021 and had no invested assets and qualifies for 6-month spending exception E 2 (B) This issuance was refunded in 2021 and had no invested assets and qualifies for 6-month spending exception A 4(B) NAME OF PROVIDER: MORGAN STANLEY CAPITAL SERVICES, INC. D 4(b) Name of provider: Morgan Stanley Capital Services, Inc. E 4(b) Name of provider: Morgan Stanley Capital Services, Inc. A Massachusetts Development Finance Agency 043431814 5758XNZ00 2021-07-28 35000000 See Part VI false false false A 0 0 35000000 0 0 0 0 0 0 0 35000000 0 2021 true false true true A false false true true true true 0.00000 0.00000 0.00000 false false 0.00000 false true A false false true false true true Morgan Stanley 39.8 false false false 0 false true A true Duval Melany Employee Housing Loan X 150000 108750 false true true Ebert Benjamin Employee Housing Loan X 500000 233334 false true true Haigis Kevin Employee Housing Loan X 100000 85833 false true true Liebow Elizabeth Employee Housing Loan X 150000 143750 false true true 571667 X 1388854 Letter from Donor X 260 18531068 Fair Market Value X 7 93596 Letter from Donor X Miscellaneous 9 513823 Letter from Donor false true false SCHEDULE M, PART I, COLUMN (B) DANA-FARBER CANCER INSTITUTE, INC. IS REPORTING THE NUMBER OF CONTRIBUTIONS RECEIVED. SCHEDULE M, PART I, LINE 33 DANA-FARBER CANCER INSTITUTE, INC. RECEIVED DONATIONS OF ART, BOOKS, AND OTHER GOODS THAT IT DISPLAYS IN ITS PROPERTIES. THESE GOODS HAVE VALUES THAT ARE EITHER NOMINAL OR ARE NOT READILY DETERMINABLE AND ARE, THEREFORE, NOT INCLUDED AS REVENUE. FORM 990, PART I, LINE 1 THE MISSION OF DANA-FARBER CANCER INSTITUTE, INC. (DFCI) IS TO PROVIDE EXPERT, COMPASSIONATE, AND EQUITABLE CARE TO CHILDREN, ADULTS, AND THEIR FAMILIES, WHILE ADVANCING THE UNDERSTANDING, DIAGNOSIS, TREATMENT, CURE, AND PREVENTION OF CANCER AND RELATED DISEASES. FORM 990, PART III, LINE 1 The Mission of DFCI is to provide expert, compassionate, and equitable care to children, adults, and their families, while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. We train new generations of clinicians and scientists, disseminate innovative patient therapies and scientific discoveries around the world, and reduce the impact of cancer, while at all times maintaining a focus on those communities who have been historically marginalized. FORM 990, PART III, LINE 4A CLINICAL CARE As one of the leading cancer centers in the world, DFCI provides compassionate, comprehensive, and personalized care to adults and children with cancer, blood disorders, and related diseases. In fiscal year 2021, our expert clinicians and caregivers at our specialized treatment centers worked together to deliver the latest therapies to our patients through 1,436 inpatient admissions, 364,577 outpatient MD visits, and 188,242 infusion treatments. Since its founding in 1947 by Sidney Farber, MD, Dana-Farber has followed his vision for a cancer center that is just as dedicated to discoveries in cancer research as it is to delivering expert, compassionate care. Dana-Farber is a founding member of Dana-Farber/Harvard Cancer Center and one of 51 NCI-designated Comprehensive Cancer Centers in the UNITED STATES. Dana-Farber is the only hospital ranked in the top four nationally by U.S. News and World Report in both adult and pediatric cancer care. In 2021, we offered more than 1,100 clinical trials. FORM 990, PART III, LINE 4B RESEARCH Scientific work at Dana-Farber is based on the premise that basic and clinical investigation are complementary and reinforcing activities. To encourage this cross-pollination of ideas, the Institute has developed an organizational framework that fosters collaborations among investigators from different disciplines. The result is an intense scientific impact on a group of diseases that continue to represent one of humanity's greatest health challenges. Some recent advances include: Immunotherapy Combination Found Effective in Non-small Cell Lung Cancer: A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non-small cell lung cancer that was resistant to a single immunotherapy agent, A CLINICAL TRIAL LED BY DANA-FARBER INVESTIGATORS SHOWED. Cellular Source of Barrett's Esophagus Identified: In two studies, Dana-Farber scientists demonstrated that Barrett's esophagus - a potential precursor of esophageal adenocarcinoma - does not involve esophageal cells turning into intestinal cells, as had long been thought, but of stomach cells adopting some of the characteristics of intestinal cells. Immunotherapy Combination Found Beneficial in Advanced Melanoma: A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a clinical trial co-led by Dana-Farber scientists. Drug Combination Can Keep Chronic Leukemia in Remission in Young Patients: Young patients with chronic lymphocytic leukemia can enjoy long remissions on the drug ibrutinib and chemotherapy, but must stay on ibrutinib indefinitely to keep the cancer in remission, Dana-Farber researchers found in a clinical trial. Vaccination Protects Against COVID-19 in Patients with Myeloma: For patients with multiple myeloma, vaccination against COVID-19 provides some protection against coronavirus infection, but to a far lower degree than the general population of cancer survivors, Dana-Farber investigators found. Targeted Drug Combination Shows Unprecedented Activity in Some Brain Tumors: A combination of two targeted cancer drugs - dabrafenib and trametinib - showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, a clinical trial led by Dana-Farber investigators showed. Discovery May Lead to Expanded Donor Pool for Stem Cell Transplants: Dana-Farber researchers found that in most cases, stem cell transplants from donors with clonal hematopoiesis, an asymptomatic blood condition, are safe and effective. Venetoclax Can Benefit Patients with Waldenstrom Macroglobulinemia: In a clinical trial led by Dana-Farber investigators, more than 80% of patients with Waldenstrom macroglobulinemia had a "major" response to a two-year course of the drug venetoclax with generally manageable side effects. Older and Younger Patients with Metastatic Colorectal Cancer Have Similar Survival: Even though young patients with metastatic colorectal cancer tend to be more fit and receive more intensive treatment than older patients, both groups survive for roughly the same amount of time, Dana-Farber researchers reported. Young Women Who Undergo Mastectomy Report Lower Quality of Life: Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, research by Dana-Farber investigators shows. Antibody-Drug Conjugate Impressive in Patients with a Form of Non-small Cell Lung Cancer: In an international clinical trial led by Dana-Farber investigators, more than half of patients with non-small cell lung cancer harboring a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug consisting of a chemotherapy agent linked to an antibody. Vitamin D May Protect Against Young-Onset Colorectal Cancer: Consuming higher amounts of Vitamin D - mainly from dietary sources - may help protect against developing young-onset colorectal cancer or precancerous colon polyps, researchers at Dana-Farber and other institutions reported in the first study to show such an association. Pain Management Worsening for Patients with Terminal Cancer: In a sign that pain management for patients dying of cancer is worsening, a study by Dana-Farber investigators found a sharp decline in opioid access among these patients over a recent 10-year period, even as many more of them turned to hospital emergency rooms for pain treatment. Cancer Screenings Rebounded After COVID-related Decline: The numbers of cancer screening tests rebounded sharply in the last quarter of 2020, following a dramatic decline in the first months of the COVID-19 pandemic, at one large hospital system in the Northeastern United States, a study by Dana-Farber researchers showed. Antibiotic Found to Kill Tumor Cells with DNA-repair Glitch: Novobiocin, an antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets, and kills cancer cells with a common genetic defect, research by Dana-Farber scientists showed. The findings spurred investigators to open a clinical trial of the drug for patients whose tumors carry the abnormality. Red Meat Consumption May Promote DNA Damage Associated with Colorectal Cancer: Genetic mutations indicative of DNA damage were associated with high red meat consumption, and increased cancer-related mortality in patients with colorectal cancer, a study led by Dana-Farber researchers found. Immunotherapy Drug Delays Kidney Cancer Recurrence: Treatment with the immunotherapy drug pembrolizumab after kidney cancer surgery prolonged the period in which patients lived without a recurrence of the cancer among patients at high risk of such recurrence, Dana-Farber researchers found. Level of Chromosomal Abnormality in Non-small Cell Lung Cancer May Predict Response to Immunotherapy: Patients with non-small cell lung cancer whose cancer cells have low levels of aneuploidy - an abnormal number of chromosomes - tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber researchers reported. New Targeted Drug Shown Effective in Patients with a Form of Uterine Cancer: In its first clinical trial in patients with uterine serous carcinoma, a hard-to-treat form of uterine cancer, the targeted drug adavosertib, which subjects tumor cells to extensive DNA damage caused tumors to shrink in nearly one-third of patients, Dana-Farber investigators reported. FORM 990, PART III, LINE 4C COMMUNITY BENEFITS The role of Dana-Farber's Community Benefits Office is to support the institute's goal to reduce cancer risk among medically underserved populations. To that end, we work with city and state health departments, community partners, and Boston-based coalitions to assess and monitor the needs of local residents with respect to cancer control. We are on the front lines of supporting and collaborating on programs designed to eliminate disparities in breast, colon, skin, and prostate cancer; educate diverse populations about tobacco cessation, human papillomavirus (HPV) prevention and screening, and clinical trials; and strengthen the support system for medically underserved populations. In short, we are committed to making Dana-Farber's care and research findings more accessible to everyone within and outside its walls. In FY 2021: A total of 1,512 individuals were reached overall through 17 community education, outreach, and screening events. program volumes have continued to be impacted by the covid-19 pandemic. The Community Benefits Office has continued to pivot to adapt to challenges related to the ongoing COVID-19 pandemic. In particular, the Community Benefits Office has continued to provide education virtually by leveraging the online platforms of community partners such as Union Capital Boston. In addition, Dana-Farber worked closely with an allocations committee to launch the Institute's determination of need community health initiative funding process virtually. Through this process, Dana-Farber awarded the first round of funding for its access to services awards, aimed at ensuring all residents, particularly those at higher risk for developing cancer and other chronic conditions, have access to coordinated and equitable health and support services. Programmatic highlights are as follows: Dana-Farber's mammography services provided 1,774 mammograms in the van and at the mammography suite at Whittier Street Health Center in Roxbury. Dana-Farber's Sun Safety program developed a COVID-19 protocol to ensure that adequate health and safety measures were followed at each screening event. In FY 2021, 11 in-person sun safety screening events were held with added health and safety measures and approval from local health departments. 484 participants were screened by a dermatologist and 133 people were referred for follow-up appointments. 65 participants were referred for a biopsy. The majority of biopsy recommendations were due to a presumptive diagnosis of basal cell carcinoma, squamous cell carcinoma or melanoma. The Tobacco Treatment program received 96 referrals and provided 125 individual tobacco cessation counseling sessions to 41 patients. 36 participants were able to reduce their total number of cigarettes smoked per day, and 10 of these reported being able to quit completely. In FY21 the Tobacco Treatment program received a grant from Friends of Dana-Farber Cancer Institute. The funds were used to provide financial incentives for patients enrolled in the smoking cessation program to encourage individuals to reduce their tobacco usage and quit smoking. Dana-Farber continues to partner with Team Maureen to lead the statewide Massachusetts HPV Coalition. This year, the Coalition's oral HPV task force launched the second edition of their dental toolkit for providers and patients in 7 languages. Dana-Farber also continues to play a leading role in the Annual HPV-Related Cancer Summit. Approximately 105 medical and dental providers, public health professionals, and community advocates attended the FY21 summit on the latest HPV research and best practices. Dana-Farber awarded the first round of funding for its access to services grants to 12 nonprofit organizations in Greater Boston to support long-lasting community health improvement and boost linkages to existing health and support services in the region. Dana-Farber committed approximately $1 million dollars to the healthy neighborhoods equity fund to address housing needs in Greater Boston. Dana-Farber partnered with Union Capital Boston and the Dana-Farber/Harvard Cancer Center to host 4 cancer awareness resource nights focused on breast and colorectal cancer screening, the HPV vaccine, cancer clinical trials, and cancer survivorship, engaging over 800 community residents virtually. These events featured an education session on a cancer-related topic, survivor testimony, and Q&A sessions with audience members. Dana-Farber launched a new partnership with myhealthfair.org to increase virtual education and outreach with the local Spanish-speaking community. In FY21, Dana-Farber was able to provide video and written educational materials, as well as promote sun safety and mammography van events. FORM 990, PART VI, SECTION A, LINE 2 FAMILY OR BUSINESS RELATIONSHIP FAMILY RELATIONSHIP: JOHN O'CONNOR AND LAURA SEN BUSINESS RELATIONSHIP: RICHARD LUBIN, CHRISTOPHER HADLEY, AND JANE BROCK-WILSON BUSINESS RELATIONSHIP: JOSH BEKENSTEIN, ANDREW KAPLAN, AND NANCY LOTANE BUSINESS RELATIONSHIP: PHILLIP GROSS AND DEMOND MARTIN Business Relationship: Andrew Janower And Michael Eisenson Form 990, Part VI, SECTION B, Line 11B PROCESS USED TO REVIEW THE FORM 990 THE DANA-FARBER CANCER INSTITUTE TAX DEPARTMENT PROVIDES ALL FINANCIAL ANALYSIS AND OTHER INFORMATION TO BE INCLUDED ON THE TAX RETURN TO ITS EXTERNAL TAX PREPARER, ERNST & YOUNG LLP, WHICH PREPARES THE DRAFT RETURN. THE DRAFT RETURN IS THEN REVIEWED BY THE DFCI TAX MANAGER, AS WELL AS THE DFCI OFFICE OF GENERAL COUNSEL AND SENIOR MANAGEMENT, BEFORE IT IS SUBMITTED FOR DFCI AUDIT COMMITTEE REVIEW. AFTER THE AUDIT COMMITTEE REVIEWS THE TAX RETURN, AN ELECTRONIC MESSAGE IS SENT TO ALL BOARD MEMBERS WITH A SECURE LINK TO THE TAX RETURN. THE BOARD HAS THE OPPORTUNITY TO REVIEW THE RETURN AND BRING ANY ISSUES TO THE ATTENTION OF THE APPROPRIATE EXECUTIVE MANAGEMENT INDIVIDUALS. A FINAL VERSION OF THE FORM IS APPROVED BY THE CFO AND FILED ELECTRONICALLY BY ERNST & YOUNG LLP WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C MONITORING & ENFORCEMENT OF CONFLICT OF INTEREST POLICY DFCI MONITORS AND ENFORCES COMPLIANCE WITH THE DFCI CONFLICT-OF-INTEREST POLICIES FOR BOARD OFFICERS, TRUSTEES, AND KEY EMPLOYEES ("COVERED PERSONS"). THE OFFICE OF THE GENERAL COUNSEL ANNUALLY DISTRIBUTES A CONFLICT OF INTEREST QUESTIONNAIRE AND CONFIDENTIALITY STATEMENT REQUIRING ALL COVERED PERSONS TO DISCLOSE INTERESTS, ROLES, AND ACTIVITIES THAT COULD GIVE RISE TO A POTENTIAL OR ACTUAL CONFLICT WITH THE INTERESTS OF DFCI. IF A TRUSTEE FAILS TO COMPLETE THE ANNUAL STATEMENT, THE CHAIR OF THE GOVERNANCE COMMITTEE MAY TAKE ACTIONS TO SUSPEND THE TRUSTEE OR CAUSE REMOVAL. DFCI REQUIRES COVERED PERSONS TO COMPLETE THE STATEMENT UPON INITIAL APPOINTMENT TO A COVERED OFFICE AND TO UPDATE THEIR DISCLOSURES ON A CONTINUING BASIS WHENEVER A COVERED PERSON BECOMES AWARE OF A NEW OR PREVIOUSLY UNDISCLOSED INTEREST. THE OFFICE OF GENERAL COUNSEL COMPARES THE DISCLOSURES TO INSTITUTIONAL INFORMATION IN ORDER TO IDENTIFY POTENTIAL OR ACTUAL CONFLICTS OF INTEREST. THE GOVERNANCE COMMITTEE OF THE DFCI BOARD OF TRUSTEES REVIEWS DISCLOSURES AND WORKS WITH THE GENERAL COUNSEL TO ADDRESS ISSUES THAT MAY ARISE. THE GOVERNANCE COMMITTEE IS RESPONSIBLE TO BRING MAJOR ISSUES RELATED TO THE CONFLICT OF INTEREST POLICY TO THE EXECUTIVE COMMITTEE AND THE ENTIRE BOARD IF DEEMED NECESSARY. THE BOARD'S CONFLICTS OF INTEREST OVERSIGHT COMMITTEE REVIEWS AND, WHEN APPROPRIATE, INSTITUTES WRITTEN MANAGEMENT PLANS TO MANAGE CONFLICTS OF INTEREST PRESENTED BY INTERESTS OF CERTAIN EXECUTIVE OFFICERS AND CERTAIN TRUSTEE INVESTMENT INTERESTS. A PROPOSED ARRANGEMENT CREATING A CONFLICT OF INTEREST MAY BE APPROVED IF APPROPRIATE STEPS ARE TAKEN TO ENSURE THAT DFCI MAKES A DECISION IN AN OBJECTIVE AND FAIR MANNER CONSISTENT WITH THE HIGHEST ETHICAL AND LEGAL STANDARDS. SUCH STEPS INCLUDE RECUSAL OF THE COVERED PERSON WITH A CONFLICT OF INTEREST FROM NEGOTIATIONS OR DISCUSSIONS ON BEHALF OF DFCI OR THE ENTITY WITH WHICH DFCI IS DOING BUSINESS AND FROM BOARD OR DFCI MANAGEMENT DISCUSSIONS OF SUCH ARRANGEMENT. FORM 990, PART VI, SECTION B, LINE 15A PROCESS FOR DETERMINING COMPENSATION OF PRESIDENT PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES REVIEWS THE PRESIDENT'S (DFCI'S CHIEF EXECUTIVE OFFICER) PERFORMANCE AND MAKES A RECOMMENDATION REGARDING COMPENSATION TO THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE ACTS ON THE RECOMMENDATION. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE COMPENSATION COMMITTEE BI-ANNUALLY COMMISSIONS AN INDEPENDENT REVIEW BY A THIRD PARTY EXECUTIVE COMPENSATION CONSULTANT TO COMPARE SUCH COMPENSATION WITH THAT OF OTHER SIMILARLY SITUATED INDIVIDUALS IN THE HEALTHCARE FIELD IN AND OUTSIDE OF THE REGION. THE DECISION OF THE EXECUTIVE COMMITTEE IS REPORTED TO THE FULL BOARD. THE BOARD COMPLETED THIS PROCESS AS OF SEPTEMBER 2020. FORM 990, PART VI, SECTION B, LINE 15B PROCESS FOR DETERMINING COMPENSATION OF OFFICERS AND KEY EMPLOYEES PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE DFCI PRESIDENT REVIEWS THE PERFORMANCE OF OFFICERS AND KEY EMPLOYEES. THE PRESIDENT MAKES A RECOMMENDATION AS TO THE COMPENSATION OF THOSE INDIVIDUALS WHO ARE DISQUALIFIED PERSONS OF DFCI TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES. THE COMPENSATION COMMITTEE APPROVES COMPENSATION FOR THOSE INDIVIDUALS BASED ON THAT RECOMMENDATION. FOR KEY EMPLOYEES WHO ARE NOT DISQUALIFIED PERSONS, THE PRESIDENT REPORTS TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES ON HER DETERMINATION OF COMPENSATION FOR THOSE INDIVIDUALS. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE PRESIDENT AND COMPENSATION COMMITTEE BI-ANNUALLY RECEIVES THE REPORT OF AN INDEPENDENT REVIEW BY A THIRD PARTY EXECUTIVE COMPENSATION CONSULTANT TO COMPARE SUCH COMPENSATION WITH THAT OF OTHER SIMILARLY SITUATED INDIVIDUALS IN THE HEALTHCARE FIELD IN AND OUTSIDE OF THE REGION. THE APPROVAL OF THE COMPENSATION COMMITTEE IS REPORTED TO THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES AND TO THE FULL BOARD. THE BOARD COMPLETED THIS PROCESS AS OF SEPTEMBER 2020. FORM 990, PART VI, SECTION C, LINE 19 AVAILABILITY OF GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS TO THE PUBLIC. GOVERNING DOCUMENTS THE GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. THE GOVERNING DOCUMENTS ARE ALSO AVAILABLE TO THE PUBLIC ON THE SECRETARY OF THE COMMONWEALTH'S WEBSITE. CONFLICT OF INTEREST POLICY DANA-FARBER CANCER INSTITUTE'S BOARD OF TRUSTEES CONFLICT OF INTEREST POLICY IS AVAILABLE UPON REQUEST. FINANCIAL STATEMENTS THE ORGANIZATION USES THE SERVICES OF DIGITAL ASSURANCE CERTIFICATION LLC (DAC) TO REPORT ANNUAL AUDITED FINANCIAL STATEMENTS AND OTHER RELEVANT ORGANIZATIONAL INFORMATION AS REQUIRED BY CERTAIN REGULATORY AND TAX LAWS. DAC IS A WEBSITE (WWW.DACBOND.COM) FREE TO THE PUBLIC THAT PUBLISHES TAX-EXEMPT BOND ISSUERS' FINANCIAL AND LEGAL DOCUMENTS SUCH AS THE AUDITED FINANCIAL STATEMENTS. FISCAL YEAR 2016 THROUGH THE LATEST ISSUE DATE OF THE AUDITED FINANCIAL STATEMENTS FOR DANA-FARBER CANCER INSTITUTE, INC. CAN BE FOUND ON THE DAC WEBSITE. ANNUAL AUDITED FINANCIAL STATEMENTS FROM FISCAL YEAR 1998 THROUGH FISCAL YEAR 2015 ARE AVAILABLE UPON REQUEST. FORM 990, PART VII, SECTION B, LINE 1 THE AMOUNT PAID TO WALSH BROTHERS, INC. INCLUDED COSTS FOR BUILDING SERVICES AND MATERIALS. HOWEVER, THE ORGANIZATION WAS UNABLE TO OBTAIN INFORMATION TO BREAKOUT THE EXACT AMOUNT FOR MATERIAL COSTS. FORM 990, PART XI, LINE 9 OTHER CHANGES IN NET ASSETS CHANGE IN INTEREST IN ASSETS HELD BY AFFILIATES $ 576,115,403 CHANGE IN VALUE OF SWAP AGREEMENT $ 13,721,943 PENSION ADJUSTMENT $ 7,027,782 ---------------------- TOTAL OTHER CHANGES IN NET ASSETS $ 596,865,128 Dana-Farber Global Oncology LLC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 851914853 Int. Oncology MA -305116 3626918 DFCI BINNEY STREET CAPITAL FUND LLC 450 BROOKLINE AVE BP418 BOSTON MA 02215 INVESTMENTS DE -457498 499998 DFI Dana-Farber Inc 450 Brookline Avenue BP418 Boston MA 02215 043102433 INVEST. MGMT. MA 501(c)(3) 12A, TYPE I DFCI true Dana-Farber Trust Inc 450 Brookline Avenue BP418 Boston MA 02215 300195757 DFCI RE HOLDI MA 501(c)(3) 12a, type 1 DFCI true DANA-FARBERMASS GEN BRIGHAM CANCER CARE 450 Brookline Avenue BP418 Boston MA 02215 043320640 ONC. RESEARCH MA 501(c)(3) 12A, type 1 NA false RMSA Trust 450 Brookline Avenue BP418 Boston MA 02215 562656539 VEBA TRUST MA 501(c)(9) N/A DFCI true Friends of Dana-Farber Cancer Institute 450 BROOKLINE AVENUE BP418 Boston MA 02215 371613621 Fundraising MA 501(c)(3) 12A, Type I DFCI true Dana-FarberChildren's Hosp Cancer Care 450 Brookline Avenue BP418 Boston MA 02215 043554536 Pediatric Onc MA 501(c)(3) 12A, type I NA false Dana-Farber Cancer Care Network Inc 450 Brookline Avenue BP418 Boston MA 02215 465138314 ONCOLOGY CARE MA 501(c)(3) 10 DFCI true MGB DF INTL LLC 399 Revolution Dr Ste 645 SOMERVILLE MA 02145 871595882 INTL. CONSULTING DE NONE 0 0 false 0 false 0.50000 false false true false false false false false false false false false true false true true false true true DANA-FARBER INC R 176705066 CASH DANA-FARBER INC S 411520290 CASH FRIENDS OF DANA-FARBER CANCER INSTITUTE INC O 295612 ACTUAL EXP FRIENDS OF DANA-FARBER CANCER INSTITUTE INC C 637605 CASH RMSA TRUST R 286572 CASH DANA-FARBER CANCER CARE NETWORK INC M 8928102 COST DANA-FARBER CANCER CARE NETWORK INC P 11276983 COST